Cardiovascular effects of endothelin-11–31 microinjected into the nucleus tractus solitarius of anesthetized rats

Neuroreport ◽  
2014 ◽  
pp. 1
Author(s):  
Peiwu Li ◽  
Xu Fu ◽  
Yan Lu ◽  
Wen Yin ◽  
Li Ma ◽  
...  
2011 ◽  
Vol 300 (1) ◽  
pp. H230-H240 ◽  
Author(s):  
Vineet C. Chitravanshi ◽  
Hreday N. Sapru

Cardiovascular effects of angiotensin-(1–12) [ANG-(1–12)] were studied in the medial nucleus of the tractus solitarius (mNTS) in anesthetized, artificially ventilated, adult male Wistar rats. Microinjections (100 nl) of ANG-(1–12) (0.06 mM) into the mNTS elicited maximum decreases in mean arterial pressure (MAP; 34 ± 5.8 mmHg) and heart rate (HR; 39 ± 3.7 beats/min). Bilateral vagotomy abolished ANG-(1–12)-induced bradycardia. Efferent greater splanchnic nerve activity was decreased by microinjections of ANG-(1–12) into the mNTS. Blockade of ANG type 1 receptors (AT1Rs; using ZD-7155 or L-158,809), but not ANG type 2 receptors (AT2Rs; using PD-123319), significantly attenuated ANG-(1–12)-induced cardiovascular responses. Simultaneous inhibition of both angiotensin-converting enzyme (ACE; using captopril) and chymase (using chymostatin) completely blocked the effects of ANG-(1–12). Microinjections of A-779 [ANG-(1–7) antagonist] did not attenuate ANG-(1–12)-induced responses. Pressure ejection of ANG-(1–12) (0.06 mM, 2 nl) caused excitation of barosensitive mNTS neurons, which was blocked by prior application of the AT1R antagonist. ANG-(1–12)-induced excitation of mNTS neurons was also blocked by prior sequential applications of captopril and chymostatin. These results indicate that 1) microinjections of ANG-(1–12) into the mNTS elicited depressor and bradycardic responses by exciting barosensitive mNTS neurons; 2) the decreases in MAP and HR were mediated via sympathetic and vagus nerves, respectively; 3) AT1Rs, but not AT2Rs, mediated these actions of ANG-(1–12); 4) the responses were mediated via the conversion of ANG-(1–12) to ANG II and both ACE and chymase were involved in this conversion; and 5) ANG-(1–7) was not one of the metabolites of ANG-(1–12) in the mNTS.


1987 ◽  
Vol 10 ◽  
pp. S40-42
Author(s):  
Danita Tsoukaris-Kupfer ◽  
Xavier Girerd ◽  
Stephane Laurent ◽  
Monique Legrand ◽  
Anne-Marie Huchet-Brisac ◽  
...  

Peptides ◽  
2006 ◽  
Vol 27 (1) ◽  
pp. 136-143 ◽  
Author(s):  
Ye Yu ◽  
Chang-lin Wang ◽  
Yun Cui ◽  
Ying-zhe Fan ◽  
Jing Liu ◽  
...  

2006 ◽  
Vol 25 (4) ◽  
pp. 653-660 ◽  
Author(s):  
Shigeki Toyoshima ◽  
Tatsuru Fukuda ◽  
Shigeru Masumi ◽  
Yoshifumi Nakashima ◽  
Yoshiro Kawaguchi ◽  
...  

1995 ◽  
Vol 269 (4) ◽  
pp. H1379-H1388 ◽  
Author(s):  
A. C. Sharma ◽  
G. Singh ◽  
A. Gulati

The role of nitric oxide (NO) in the cardiovascular actions of diaspirin cross-linked hemoglobin (DCLHb) was studied in anesthetized rats. The regional circulatory and systemic hemodynamic effects of DCLHb (400 mg/kg iv) were studied using a radioactive microsphere technique in control (untreated) and L-arginine (a NO precursor) pretreated rats. DCLHb produced a significant increase in blood pressure (75%), cardiac output (42%), stroke volume (36%), and total peripheral resistance (45%), without affecting heart rate, when administered to control rats. L-Arginine pretreatment significantly attenuated DCLHb-induced systemic hemodynamic effects. DCLHb-induced increase in blood flow to the skin and spleen was completely blocked, and that to the heart was partially blocked, by L-arginine pretreatment, suggesting that cardiovascular actions induced by DCLHb could be antagonized by the NO precursor L-arginine. The NO synthase (NOS) inhibitor NG-nitro-L-arginine methyl ester (L-NAME) produced significant increases in regional vascular resistance, leading to a decrease in blood flow to all the organs except the heart, where an increase in blood flow and a decrease in vascular resistance was observed. DCLHb, when administered in L-NAME-pretreated rats, accentuated the decrease in blood flow to the gastrointestinal system, spleen, mesentery and pancreas, skin, and musculoskeletal system. These studies provide evidence that the NO precursor L-arginine can attenuate the effects of DCLHb and that DCLHb can potentiate the effect of the NOS inhibitor L-NAME. The role of NO in the mechanism of action of DCLHb was further studied by estimating plasma guanosine 3',5'-cyclic monophosphate (cGMP) in control, DCLHb-treated, L-NAME-treated, and L-NAME followed by DCLHb-treated rats. DCLHb and L-NAME significantly decreased the concentration of circulating cGMP in blood plasma. L-NAME pretreatment potentiated DCLHb-induced decrease in cGMP levels. Because the formation of cGMP is stimulated by NO, these studies provide additional evidence for the involvement of NO in the mechanism of action of DCLHb. It is concluded that NO plays an important role in the cardiovascular effects of DCLHb.


1996 ◽  
Vol 720 (1-2) ◽  
pp. 183-190 ◽  
Author(s):  
Sordaini M. Caligiorne ◽  
Robson A.S. Santos ◽  
Maria J. Campagnole-Santos

Sign in / Sign up

Export Citation Format

Share Document